Ponce Therapeutics, Inc. reunites the team that founded Bellicum Pharmaceuticals and took it public in 2014 with a $161 million IPO. The team is retooling their original cell control technology with state-of-the-art advances towards their new goal of creating anti-aging products with a solid underlying scientific basis that actually work.
- The science of aging has continued to mature and can now provide a scientific basis for technologies to reverse the aging process in humans
- Proof of concept data in animal models demonstrates that removal of senescent cells from organs improves their function and imbues them with a more youthful profile
- Targeting p16-expressing cells for apoptotic elimination is one approach to removing senescent cells from the body
- Our lead product is a topical ointment containing nanoparticles carrying our proprietary rapaCIDe cell elimination technology targeted to p16-expressing keratinocytes
- Our Phase I clinical trial program targets in situ carcinoma of the skin (Bowen’s disease) and seborrheic keratoses, which are nearly ubiquitous in the aging population, and which express high levels of p16
- We plan to extend our clinical portfolio to include multiple other indications to reverse aging
Reuniting the founders of Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM)
Before joining Bellicum, he served as the Vice Chairman of Pathology and Immunology at Baylor College of Medicine, where he was the Roger D Rossen Endowed Professor of Immunology. His lab focused on anti-cancer vaccination and animal modeling for prostate cancer, but his collaborative interests stretched into most areas of biology, such as Gene Regulation, Development, Cancer, Immunology and Aging. The animal models developed in his lab included the EZC-Prostate™ model for identifying and developing novel androgen axis inhibitors and the JOCK1 inducible prostate cancer model that demonstrated a critical inductive role of the Fibroblast Growth Factor Receptor 1(FGFR1) Axis in prostate cancer development.
He has published extensively in top scientific and medical journals, including Science, Nature, Nature Medicine, Molecular Cell, and NEJM and is also an inventor on at least 10 patent families, reflecting many areas of regulated cellular therapy. Dr. Spencer earned his BS in Chemistry (magna cum laude) at the University of California in San Diego and his Ph.D. in Biology from the Massachusetts Institute of Technology. He completed his postdoctoral degree at the Howard Hughes Medical Institute at Stanford University.
Through an agreement with Ponce Therapeutics, Inc., he currently also provides limited consulting CSO services to NanoCell Technologies, Inc.